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Current strategies to accelerate hematopoietic reconstitution after transplantation include transplantation
of greater numbers of hematopoietic stem/progenitor cells (HSPCs) or ex vivo expansion of harvested
HSPCs before transplant. However, the number of cells available for transplantation is usually low, and
strategies to expand HSPCs and maintain equivalent engraftment capability ex vivo are limited. We noted
that activated granulocyte-derived cationic peptides positively primed responsiveness of HSPCs to a
CXCL12 gradient. Accordingly, we noted that accelerated homing/engraftment of β-defensin-2, a well-
known antimicrobial cationic peptide, primed bone marrow nucleated cells (BMNCs) compared to normal
BMNCs after transplantation into lethally irradiated recipients. We envision that small cationic peptides,
which primarily possess antimicrobial functions and are harmless to mammalian cells, could be applied
to prime HSPCs before transplantation. This novel approach would be particularly important in cord
blood transplantation, where the number of HSPCs available for transplantation is usually limited.
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Hematopoietic stem/progenitor cells (HSPCs) circulate in
peripheral blood (PB) under steady state conditions at very
low levels to keep a pool of stem cells in balance in the
bone marrow (BM) microenvironment [1-4]. Therefore, the
bloodstream might be the “highway” by which HSPCs relocate
between circulation in blood vessels and lodgment in BM
endosteal and endothelial niches.
HSPCs can be mobilized from BM into PB during tissue
injury [5,6], as well as after treatment of several mobilizing
agents. Granulocyte colony-stimulating factor (G-CSF) is
currently the most frequently used drug that may efficiently
mobilize HSPCs after a few consecutive daily injections [7-
9]. On the other hand, the collective term ‘homing’ refers
to the early stages of BM seeding by HSPCs after transplantation,
which precedes engraftment, proliferation, and differentiation
of these cells into the hematopoietic lineage. In general,
homing, engraftment, and expansion of HSPCs after
transplantation are closely related processes [10,11].
Transplantation of HSPCs is dependent on the successful
homing, engraftment, and repopulation of stem cells in the
BM [12,13]. Stem cell homing through the circulatory system
to the BM is the critical first step in this process.
The interaction of CXCL12 with its receptor CXCR4, which
is expressed in HSPCs, has been implicated as a primary
axis governing HSPC homing and engraftment into the BM
following transplantation [14-16]. Current strategies to
accelerate hematopoietic reconstitution after transplantation
include transplantation of greater numbers of HSPCs or ex
vivo expansion of harvested HSPCs before transplant.
However, the number of cells available for transplantation
is usually low, and strategies to expand HSPCs and maintain
equivalent engraftment capability ex vivo are limited [17,18].
*Corresponding author: Kyong Soo Park, Department of Internal Medicine, Seoul National University College of Medicine, 28
Yeongeon-dong, Chongno-gu, Seoul 110-744, Republic of Korea
Tel: +82-2-2072-2946; Fax: +82-2-3668-7655; E-mail: kspark@snu.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Lab Anim Res 2011: 27(2), 133-140
DOI: 10.5625/lar.2011.27.2.133134 Hakmo Lee et al.
Lab Anim Res | June, 2011 | Vol. 27, No. 2
The migration of HSPCs toward a CXCL12 gradient has
been correlated with the repopulating potential of transplanted
HPSCs. Indeed, it has been demonstrated that successful
homing and engraftment of HSPCs is significantly reduced
if the CXCR4-CXCL12 axis is impeded [19].
Of note, it has been shown that leukapheresis products
(i.e., C3 liquid-phase cleavage fragments, C3a) are known
to enhance responsiveness of HSPCs to a CXCL12 gradient
[20,21]. The molecular explanation of this phenomenon was
that C3a increases CXCR4 incorporation into membrane lipid
rafts, thus facilitating its more effective assembly with
downstream signaling molecules [22].
In fact, C3a is one of the antimicrobial cationic peptides
(AMPs), which have antimicrobial activity [23]. AMPs have
been demonstrated to kill bacteria, enveloped viruses, fungi,
and even transformed or cancerous cells without affecting
the viability of eukaryotic cells. Selective effects of AMPs,
like membrane perturbation of eukaryotic cells and killing
of prokaryotic cells, are known to be dependent on the
characteristics of membranes, such as the presence of
cholesterol and membrane electric charge [24].
In addition, leukapheresis products which are enriched in
activated granulocytes are known to release several cationic
peptides and activate complement cascades [13]. We recently
noted that activated granulocyte-derived cationic peptide
positively primes responsiveness of murine HSPCs to a CXCL12
gradient [25].
Based on these data, we hypothesized that the use of cationic
peptides as priming drugs might also enhance homing and
engraftment of HSPCs after transplantation. In this study,
we tested if human β defensin-2 (hBD-2), a well-known
antimicrobial cationic peptide released from activated




C57BL/6 mice were adopted at 1-2 weeks and used for
experiments at age 6 to 8 weeks. Animal studies were approved
by the Animal Care and Use Committee of the Institute of
Laboratory Animal Resources, Seoul National University.
Bone marrow nucleated cells (BMNCs)
BMNCs were prepared by flushing femurs and tibias of
pathogen-free, 6- to 8-week-old mice without enzymatic
digestion. They were lysed with BD Pharm Lyse buffer (BD
Biosciences, San Jose, CA, US) to remove red blood cells
(RBCs), washed, and resuspended in appropriate media for
further analysis.
Trans-well migration assay
The trans-well migration assay was performed as described
elsewhere [25]. Briefly, unless otherwise indicated, RBC-lysed
BMNCs from C57BL/6 mice were resuspended in assay
media (RPMI containing 0.5% bovine serum albumin) and
equilibrated for 30 min at 37
oC. Six hundred-fifty microliters
of assay media in the presence or absence of CXCL12 (50-
300 ng/mL, PeproTech, Rocky Hill, NJ, USA) was added to
the lower chambers of a Trans-well 24-well plate (Costar
Corning, Cambridge, MA, USA). hBD-2 was purchased from
Prospec (East Brunswick, NJ, USA). Aliquots of normal or
30 min hBD-2-exposed cell suspension (1×10
6 cells/100 µL)
were loaded onto the upper chambers with 5 µm-pore filters,
which were incubated for 3 hours at 37
oC, 95% humidity,
and 5% CO2. Cells from the lower chambers were scored
using FACS analysis for migration of BMNCs to test reagents.
The results are presented as a migration index, i.e., fold increase
of cell numbers migrated toward the lower well compared
to control media. In some experiments, migrated cells
harvested from the lower chambers were plated in semisolid
clonogenic assays supplemented with cytokines and were
stimulated to grow colony-forming units-granulocyte-macrophage
(CFU-GM) and colony-forming units-macrophage (CFU-M)
as described elsewhere [25].
Colony forming unit assay
Red blood cells were lysed with BD Pharm Lyse buffer.
Nucleated cells were subsequently washed twice and used
for CFU-GM and/or CFU-M colonies. BMNCs were
resuspended in human methylcellulose base media provided
by the manufacturer (R&D Systems, Minneapolis, MN, USA)
supplemented with 25 ng/mL recombinant murine granulocyte
macrophage colony-stimulating factor (mGM-CSF) and 10
ng/mL recombinant murine interleukin-3 (mIL-3) for CFU-
GM, 10 ng/mL recombinant murine macrophage stimulating
factor (mM-CSF) for CFU-M. Cultures were incubated for
7 days, at which time they were scored for the number
of CFU-GM colonies under an inverted microscope.
Phosphorylation of intracellular pathway proteins
Western blot analysis was performed on extracts prepared
from mouse EL4 cell lines that had been kept in RPMI medium
containing 0.5% bovine serum albumin (BSA) to render the
cells quiescent. Cells were stimulated with either a low or
high concentration of CXCL12 (50 ng/mL or 300 ng/mL) inOptimization of HSPC transplantation efficiency 135
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the presence or absence of hBD-2 for 90 sec at 37
oC and
then lysed for 10 min on ice in M-Per lysing buffer (Pierce,
Rockford, IL, USA) containing protease and phosphatase
inhibitors (Sigma, St. Louis, MO, USA). Extracted proteins
were separated on a 10% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) gel and then
transferred to a nitrocellulose membrane (Hybond ECL;
Amersham Life Sciences, Little Chalfont, United Kingdom).
Phosphorylation of 44/42 MAPK protein was detected by
protein immunoblotting using mouse monoclonal 44/42
phospho-specific MAPK antibody (New England Biolabs,
Beverly, MA, USA), with horseradish peroxidase conjugated
goat anti-mouse immunoglobulin G (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) as secondary antibody. Equal loading
in the lanes was evaluated by stripping the blots and reprobing
them with the appropriate monoclonal or polyclonal
antibodies. The membranes were developed with an ECL
reagent (Amersham Life Sciences), dried, and exposed to
film (HyperFilm; Amersham Life Sciences).
In vitro adhesion assay
Wild-type BM stromal cells were grown to confluence, and
normal or 30 min hBD-2-exposed BMNCs were subsequently
plated over BM-derived stroma feeder layers established in
well plates. Five minutes later, plates were gently shaken,
and non-adherent cells were discarded. Subsequently, the
cultures were trypsinized and stimulated to grow CFU-GM
colonies as mentioned earlier. The number of colonies was
scored under an inverted microscope.
Evaluation of in vivo engraftment of transplanted
HSPCs
To test whether hBD-2 priming enhanced homing and
engraftment of transplanted HSPCs, we used a short-homing
assay to evaluate lodging of HSPCs to the spleen and bone
marrow. Normal recipient mice were lethally irradiated (950
cGy) and 24 hours later were transplanted with 5×10
5 normal
or 30 min hBD-2-exposed BMNCs by tail vein injection. At
18 hours or 12 days after BMNC transplantation, spleens
were removed and fixed for colony forming units-spleen (CFU-
S) count. At the same time, BM were harvested from the
femurs and plated in methylcellulose cultures and stimulated
to grow CFU-GM colonies. CFU-S was also counted.
Statistical analysis
Arithmetic means and SD were calculated using Instat 1.14
software (GraphPad, San Diego, CA, USA). Statistical significance
was defined as P<0.05. Data were analyzed using an unpaired
Student's t-test.
Results
CXCL12 directly chemoattracts BM cells in a dose-
dependent manner
To optimize the trans-well migration assay we tested different
doses of CXCL12 using a 5 µm pore sized trans-well. CXCL12
directly chemoattracted not only BMNCs (Figure 1A), but
also CFU-GM progenitor cells (Figure 1B) in a dose-dependent
manner. However, CXCL12 at a concentration lower than
25 ng/mL did not chemoattract either BMNCs or CFU-GM
progentitor cells efficiently. Significant migrations of BMNCs
to CXCL12 were shown in concentrations of 50 ng/mL or
higher. Although 50 ng/mL of CXCL12 is relatively high
compared to its physiological plasma concentration [26], we
chose 50 ng/mL of CXCL12 as the standard concentration
for our experiments based on the results obtained from our
optimization assay.
hBD-2  stimulation  enhanced  responsiveness  of
HSPCs to a CXCL12 gradient in a dose-dependent
manner
The antimicrobial cationic peptide hBD-2, which is known
to be released from activated human granulocytes, enhanced
responsiveness of BMNCs to a CXCL12 gradient. As expected,
the migration of hBD-2-exposed BMNCs to a CXCL12 gradient
was significantly enhanced compared to that of normal BMNCs
(Figures 2A and 2B). This accelerated migration of BMNCs
and CFU-GM progenitor cells to a CXCL12 gradient was
dependent on the hBD-2 concentration used. However, hBD-
2 itself did not show a direct chemotactic effect on BMNCs
(Figure 2C) and CFU-GM progenitor cells (Figure 2D).
Figure 1. Migration of BMNCs and CFU-GM progenitor cells to
a CXCL12 gradient. CXCL12 directly chemoattracts CFU-GM
progenitor cells as well as BMNCs. Migration of BMNCs (A)
and CFU-GM progenitor cells (B). Values are the fold increase
of migrated cell numbers compared to media alone control.
CXCL12 (ng/mL). *P<0.05 as compared with media alone
control. The data shown represent the combined results from
three independent experiments carried out in duplicate per
group (n=6).136 Hakmo Lee et al.
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Considering hBD-2 is known to use CCR6 for signal
transduction, the hBD-2 priming effect was not a receptor-
mediated phenomenon. MIP-3α, which is known as an agonist
for CCR6, did not enhance migration of BMNCs to the CXCL12
gradient (data not shown). These results strongly support that
enhanced migration of hBD-2-primed cells might be mediated
by enhancing incorporation of CXCR4 into lipid rafts as similar
to what was shown in C3a primed cells [20,21].
hBD-2 enhanced CXCL12-CXCR4-mediated intracellular
signaling strength
We tested if enhanced CXCR4 incorporation into membrane
lipid rafts in the presence of hBD-2 is better connected to
downstream signaling machinery and can respond robustly
to a CXCL12 gradient, as a previous report showed that the
supernatants of leukapheresis products increased p42/44
MAPK phosphorylation mediated by enhancing incorporation
of CXCR4 into membrane lipid rafts [20,21].
We noticed that hBD-2 itself does not induce phosphorylation
of p42/44 MAPK but enhanced p42/44 MAPK phosphorylation
induced by CXCL12 in EL4 cells. CXCL12-induced
phosphorylation of p42/44 MAPK was strongly enhanced in
hBD-2-primed cells (Figure 3A). This also strongly supports
that the priming effect of hBD-2 is not mediated by receptor-
ligand interactions.
hBD-2 priming increased the adhesion of CFU-
GM progenitor cells to BM stromal cells
We questioned the effects of priming agents on other
processes essential for the engraftment of HSPCs, as they
must adhere to the BM stroma to proliferate and differentiate.
To address this question further, we carried out in vitro adhesion
experiments with BMNCs. We found that hBD-2-exposed
CFU-GM progenitor cells showed increased adhesion (Figure
3B). We suggest that hBD-2, by enhancing responsiveness
of HSPCs to a CXCL12 gradient, may directly modulate HSPC
homing.
hBD-2  exposure  to  BMNCs  accelerated  homing/
engraftment  after  transplantation  into  lethally
irradiated mice
Based on our in vitro results showing enhanced migration
and adhesion, we examined whether hBD-2-primed BMNCs
engraft faster than normal BMNCs. As summarized in Table
1, hBD-2-primed BMNCs homed better to the BM and spleen
of lethally irradiated recipient mice. CFU-GM progenitor cells
at 18 hours after BMNC transplantation were increased more
than two fold in the femur of hBD-2-primed BMNC
transplanted group compared to the normal BMNC
transplanted group (data not shown). No CFU-GM or CFU-
S was recovered from lethally irradiated control mice that
did not receive BMNCs.
hBD-2  exposure  to  BMNCs  did  not  affect  the
viability  and  differentiation  potential  of  BM
progenitor cells
Finally, we evaluated the safety of hBD-2 exposure on
hematopoietic progenitor cells. BMNCs (5×10
5/mL) were
incubated for 60 min at 37 CO2 incubator in the absence
or presence of hBD-2 at 0.12, 0.25, or 0.50 µg/mL
concentrations. These cells were subsequently examined via
in vitro colony forming assays for the number of CFU-GM
and CFU-M progenitor cells. As expected, hBD-2 exposure
did not affect the viability and the clonogeneic potential of
HSPCs (Figures 4A and 4B).
Discussion
Homing is the first step into BM seeding by HSPCs after
transplantation, which precedes their engraftment, proliferation,
Figure 2. The cationic peptide hBD-2 enhances responsive-
ness of BM cells to a CXCL12 gradient. The migration of hBD-
2-exposed BMNCs was significantly enhanced compared to
that of normal BMNCs (A, BMNCs; B, CFU-GM progenitors) in
response to a CXCL12 gradient. However, hBD-2 itself did not
show direct chemotactic effect to BMNCs (C) and CFU-GM
progenitor cells (D). Values are the fold increase of migrated
cell numbers compared to control. CXCL12 (ng/mL), hBD-2
(µg/mL). *P<0.05 as compared to CXCL12 (50 ng/mL, A and B)
or media alone control (C and D). The data shown represent
the combined results from three independent experiments
carried out in triplicate per group (n=9).Optimization of HSPC transplantation efficiency 137
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and differentiation. It is also well established that the CXCL12-
CXCR4 axis plays a pivotal role in directing the homing of
HSPCs from the PB to the BM [10,27,28]. While CXCL12
is expressed in the BM stroma, CXCR4 is present on the
surface of HSPCs [29,30]. It is not surprising that proper
functioning of the CXCL12-CXCR4 axis is crucial in directing
the homing and engraftment of HSPCs into the BM after
transplantation.
It has been recently demonstrated that CXCR4 requires
an association with membrane lipid rafts for proper signaling
function [31-34]. Additionally, it has been shown that
membrane lipid rafts are important for T-cell polarization and
chemotaxis [35]. Increased responsiveness of HSPCs to a
CXCL12 gradient in the presence of other factors was named
as the priming effect [36]. Previous work revealed that several
small molecules (i.e., fibronectin and fibrinogen fragments,
hyaluronic acid, granulocyte-derived cationic peptides, and
C3a) that are present in supernatants from leukapheresis
products may modulate the responsiveness of HSPCs to a
CXCL12 gradient by enhancing the incorporation of CXCR4
into membrane lipid rafts [37-39].
In this study, we evaluated if the cationic peptide hBD-
2 released from activated granulocytes will enhance homing
and engraftment of transplanted HSPCs. We found that HSPCs
stimulated by hBD-2 better responded to a CXCL12 gradient.
Moreover, we found for the first time that transplantation
of hBD-2-primed BMNCs into lethally irradiated recipients
results in an increase in the number of donor-derived CFU-
granulocyte-macrophage progenitors in the bone marrow
cavities, as well as an increase in formation of CFU-S.
hBD-2 itself did not show chemotactic activity but an
enhanced migration of HSPCs to a CXCL12 gradient compared
to normal cells. Pretreatment of HSPCs with hBD-2 enhanced
CXCL12-CXCR4-mediated intracellular signaling, adhesion to
stromal cells, and their engraftment into irradiated mice, further
Figure 3. hBD-2 enhances p42/44 MAPK phosphorylation mediated by CXCL12. Downstream signaling mediated by the CXCL12-
CXCR4 axis was strongly enhanced when CXCL12 was employed together with hBD-2 (A). hBD-2-primed CFU-GM progenitor
cells showed enhance adhesion onto stromal cells (B). CXCL12 (L, 50 ng/mL; H, 300 ng/mL), hBD-2 (1 µg/mL). *P<0.05 as
compared to non-primed CFU-GM progenitor cells. The data shown represent the combined results from three independent
experiments carried out in duplicate per group (n=6).
 
Table 1. In vivo engraftment of BMNCs and CFU-GM progenitor cells 12 days after transplantation
Cell sources BMNCs/femur CFU-GM/femur CFU-S/femur
Normal (n=5) 1,333,500.0±78.60 4,868.1±306.6 8.60±1.52
hBD-2-primed (n=5) 2,443,750.0±339.4 9,025.6±854.0 16.80±0.840
Values (mean±SD) shown are the combined results from 5 mice per group (n=5).
Figure 4. hBD-2 exposure on BMNCs does not affect the
viability and differentiation potential of BM-derived HSPCs.
BMNCs were exposed to different doses of hBD-2 for 60
minutes at 37
oC before the colony forming assay. CFU-GM (A)
and CFU-M (B) differentiation of BMNCs. No significant
differences were observed between normal or hBD-2 primed
BMNCs. The data shown represent the combined results from
two independent experiments carried out in duplicate per group
(n=4).138 Hakmo Lee et al.
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emphasizing that hBD-2 plays an essential role in promoting
the homing and engraftment of HSPCs to the bone marrow
through its synergistic interaction with the CXCL12-CXCR4
signaling axis.
Considering the fact that CXCL12, secreted by bone marrow
stromal cells, regulates the migration of HSPCs and thereby
plays a central role in anchoring stem cells to the bone marrow
microenvironment after transplantation, the sensitization of
the CXCL12-CXCR4 axis by hBD-2 could be used to accelerate
the homing and migration of transplanted HSPCs into the BM.
Activated granulocyte-derived AMPs might be safer than
previously described priming agents (C3a, angiopoietin etc.)
[20,21,40], because AMPs have been demonstrated to kill
bacteria, enveloped viruses, fungi, and even transformed or
cancerous cells without affecting the viability of eukaryotic
cells. Selective effects of AMPs, like membrane perturbation
of eukaryotic cells and killing of prokaryotic cells, are known
to be dependent on the characteristics of membranes, such
as cholesterol content or membrane electric charge. In
agreement with our hypothesis, hBD-2 exposure did not affect
the viability and differentiation potential of HSPCs.
Taken together, we suggest that hBD-2 might be employed
as a new agent to prime ex vivo HSPCs before transplantation.
This novel approach would be particularly important in
umbilical cord blood transplantation, where the number of
HSPCs available for reconstitution of recipient is often limited.
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